As the Supreme Court prepares to rule on President Trump’s tariffs in the coming weeks, administration officials are betting that the sheer complexity of unwinding billions in collected import taxes ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
With the Bank of Japan (BOJ) expected to hike rates next week, some observers are worried that the Japanese yen could surge, triggering an unwinding of "carry trades," crushing bitcoin. Their analysis ...
Welcome to Soundtrack Sunday, where a member of the PC Gamer team takes a look at a soundtrack from one of their favourite games—or a broader look at videogame music as a whole—offering their thoughts ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
An unwinding in popular momentum stocks is picking up speed on Thursday. The GS USA High Beta Momentum Basket was off 6.7% in recent trading, on track for its worst day since January, according to ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback